Nanobiotix shares fall 5.5%, among the largest declines in the SBF 120
The Paris-based oncology nanomedicine biotech gives back part of its strong November rebound, in a broadly stable Paris market. The decline comes as management is set to address the financial community in London.
A decline that places the stock at the bottom of the SBF 120
As the market closes, Nanobiotix shares are down 5.3% at €26.42, while the SBF 120 remains stable (+0.01%).
The stock is among the largest decliners in the index, behind Eramet and Inventiva, and this drop reduces its monthly gain to nearly 34%. It also comes with a move below the MM20 (€27.31), while the MM50 (€26.59) is less than 1% from the price.
The stock remains below its MM200, at €29.79, a gap of 11.3%, which shows that this month's rebound has not yet brought the share price back to its long-term trend. This decline extends the alternation of rising and falling sessions observed since the beginning of the month.
London meetings and cash runway through 2029
Nanobiotix is scheduled to present at the Jefferies and UBS conferences in London on November 16 and 17, according to a press release published on November 9. The company is developing NBTXR3 (JNJ-1900), a radioamplifier used in combination with radiotherapy, in partnership with Johnson & Johnson.
When it published its first-half 2026 financial results on September 24, it reported cash of €110.9 million, sufficient to fund its operations through 2029.
The stock is listed in Paris and as ADSs on the Nasdaq, where the index is down 2.15% this Monday: the Paris shares close their session at 5:30 p.m., before the Nasdaq closes its own session.
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.